- Approval Id
- aa1b6a04dafa176d
- Drug Approval Emc Name
- Nitrofurantoin CNX Therapeutics 100 mg Prolonged-Release Capsules
- Drug Name
- Nitrofurantoin CNX Therapeutics 100 mg Prolonged-Release Capsules
- Company Name
- CNX Therapeutics Ltd (formerly Sunovion Pharmaceuticals Europe)
- Company Address
- 3rd Floor, LABS House, 15-19 Bloomsbury Way, London, WC1A 2TH, UK
- Company Website
- //www.cnx-therapeutics.com
- Company Telephone
- +44 (0)207 821 2840
- Company Medical Info Direct Line
- + 44 (0)207 821 2840
- Company Medical Info Email
- medinfo@cnx-therapeutics.com
- Company Customer Care Direct Line
- +44 (0)207 821 2840
- Atc Code
- J01XE01
- Legal Category
- Prescription only medicine
- Authorisation Holder
- CNX Therapeutics Ltd
3 Bunhill Row
London
EC1Y 8YZ
UK
- Authorisation Number
- PL 19635/0006
- Authorisation Date
- Date of first authorization: 07.05.2024
- Instruction Authorisation Holder
- CNX Therapeutics Ltd
3 Bunhill Row
London
EC1Y 8YZ
UK
- Instruction Authorisation Number
- PL 19635/0006
- Instruction Authorisation Date
- Date of first authorization: 07.05.2024
- Instruction Composition
- Each prolonged-release hard capsule contains the equivalent of 100 mg nitrofurantoin in the form of nitrofurantoin macrocrystals and nitrofurantoin monohydrate.
\*\*Excipients with known effect:\*\*
Each capsule contains 74 mg lactose and 33 mg sucrose.
For the full list of excipients, see section 6.1.
- Instruction Dosage Form
- Hard prolonged-release capsule
Each capsule is 19.4 mm long and 6.9 mm wide and has a blue opaque cap with “NTRF” debossed in white ink and a yellow opaque body.
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
For the treatment of and prophylaxis against acute or recurrent, uncomplicated lower urinary tract infections or pyelitis either spontaneous or following surgical procedures. It is indicated in adults, children and infants over 12 years of age.
Nitrofurantoin is specifically indicated for the treatment of infections when due to susceptible strains of \*\*Escherichia coli\*\*, Enterococci, Staphylococci, \*\*Citrobacter\*\*, \*\*Klebsiella\*\* and \*\*Enterobacter\*\*.
Most strains of Proteus and \*\*Serratia\*\* are resistant. All \*\*Pseudomonas\*\* strains are resistant.
Nitrofurantoin is not indicated for the treatment of associated renal cortical or perinephric abscesses.4.2 Posology and method of administration
\*\*Posology\*\*
\*Adults and children over 12 years of age.\*
The dose should be taken with food or milk (e.g. at meal times).
Acute or recurrent uncomplicated UTI and pyelitis -100mg twice daily for seven days.
Surgical Prophylaxis - 100 mg twice daily on the day of the procedure and 3 days thereafter.
\*Elderly\*
Provided there is no significant renal impairment, in which nitrofurantoin is contraindicated, the dosage should be that for any normal adult.
See precaution and risks to elderly patients associated with long term therapy (see section 4.8).
\*Children under 12 years\*
Nitrofurantoin CNX Therapeutics 100mg Prolonged-Release Capsules is a fixed dosage and is therefore not suitable for children under 12 years.
\*Renal impairment\*
Nitrofurantoin is contraindicated in patients with renal dysfunction and in patients with an eGFR below of less than 45 ml/minute (see sections 4.3 & 4.4).
\*\*Method of administration\*\*
For oral use4.3 Contraindications
• Hypersensitivity to the active substance, other nitrofurans or to any of the excipients listed in section 6.1.
• Patients suffering from renal dysfunction with an eGFR below 45 ml/minute.
• G6PD deficiency (see also Section 4.6)
• Acute porphyria.
• In infants under three months of age as well as pregnant patients at term (during labour and delivery) because of the theoretical possibility of haemolytic anaemia in the foetus or in the newborn infant due to immature erythrocyte enzyme systems.4.4 Special warnings and precautions for use
Nitrofurantoin is not effective for the treatment of parenchymal infections of a unilaterally functioning kidney. A surgical cause for infection should be excluded in recurrent or severe cases.
Nitrofurantoin may be used with caution as short-course therapy only for the treatment of uncomplicated lower urinary tract infection in individual cases with an eGFR between 30-44 ml/min to treat resistant pathogens, when the benefits are expected to outweigh the risks.
Since pre-existing conditions may mask hepatic or pulmonary adverse reactions, nitrofurantoin should be used with caution in patients with pulmonary disease, hepatic dysfunction, neurological disorders and allergic diathesis.
Peripheral neuropathy and susceptibility to peripheral neuropathy, which may become severe or irreversible has occurred and may be life threatening. Therefore, treatment should be stopped at the first signs of neural involvement (paraesthesiae).
Nitrofurantoin should be used with caution in patients with anaemia, diabetes mellitus, electrolyte imbalance, debilitating conditions, and vitamin B (particularly folate) deficiency.
\*Pulmonary adverse reactions\*
Acute, subacute and chronic pulmonary reactions have been observed in patients treated with nitrofurantoin. If these reactions occur, nitrofurantoin should be discontinued immediately. Signs of pulmonary damage include difficulty and or pain when breathing, shortness of breath and coughing up blood or mucus.
\*Chronic pulmonary reactions\*
Chronic pulmonary reactions (including pulmonary fibrosis and diffuse interstitial pneumonitis) can develop insidiously and can often occur in elderly patients. Close monitoring of the lung diseaseof patients receiving long-term therapy is indicated (especially in the elderly).
\*Acute pulmonary reactions\*
Pulmonary reactions may be acute and usually occur within the first week of treatment. Increased vigilance for respiratory symptoms in patients who have just started therapy is warranted (especially in the elderly).
Urine may be coloured yellow or brown after taking Nitrofurantoin. Patients on Nitrofurantoin are susceptible to false positive urinary glucose (if tested for reducing substances).
Nitrofurantoin should be discontinued at any signs of haemolysis in those with suspected glucose-6-phosphate dehydrogenase deficiency.
Gastrointestinal reactions may be minimised by taking the drug with food or milk, or by adjustment of dosage.
\*Hepatotoxicity\*
Hepatic reactions, including hepatitis, autoimmune hepatitis, cholestatic jaundice, chronic active hepatitis, and hepatic necrosis, occur rarely. Fatalities have been reported. The onset of chronic active hepatitis may be insidious, and patients should be monitored periodically for changes in biochemical tests that would indicate liver injury. If hepatitis occurs, the drug should be withdrawn immediately and appropriate measures should be taken.
For long term treatment monitor the patient closely for appearance of hepatic or pulmonary symptoms and other evidence of toxicity.
Discontinue treatment with nitrofurantoin if otherwise unexplained pulmonary, hepatotoxic, haematological or neurological syndromes occur.
\*\*Excipients\*\*
Nitrofurantoin CNX Therapeutics 100 mg prolonged-release capsules contain lactose monohydrate and sucrose. Patients with rare hereditary problems of galactose intolerance, fructose intolerance, total lactase deficiency, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.4.5 Interaction with other medicinal products and other forms of interaction
1. Increased absorption with food or agents delaying gastric emptying.
2. Decreased absorption with magnesium trisilicate.
3. Decreased renal excretion of Nitrofurantoin by probenecid and sulfinpyrazone.
4. Decreased anti-bacterial activity by carbonic anhydrase inhibitors and urine alkalisation.
5. Anti-bacterial antagonism by quinolone anti-infectives.
6. Interference with some tests for glucose in urine.
7. As Nitrofurantoin belongs to the group of Antibacterials, it will have the following resulting interactions:
• Typhoid Vaccine (oral): Antibacterials inactivate oral typhoid vaccine.4.6 Fertility, pregnancy and breastfeeding
\*\*Pregnancy\*\*
Animal studies with nitrofurantoin have shown no teratogenic effects. Nitrofurantoin has been in extensive clinical use since 1952 and its suitability in human pregnancy has been well documented. However, as with all other drugs, the maternal side effects may adversely affect course of pregnancy. The drug should be used at the lowest dose as appropriate for a specific indication, only after careful assessment.
Nitrofurantoin is however contraindicated in infants under three months of age and in pregnant women during labour and delivery because of the possible risk of haemolysis of the infants immature red cells.
\*\*Breast-feeding\*\*
Breast feeding an infant known or suspected to have an erythrocyte enzyme deficiency (including G6PD deficiency), must be temporarily avoided, since Nitrofurantoin is detected in trace amounts in breast milk.
\*\*Fertility\*\*
No data available4.7 Effects on ability to drive and use machines
Nitrofurantoin CNX Therapeutics 100 mg Prolonged-Release Capsules may cause dizziness and drowsiness. Patients should be advised not to drive or operate machinery if affected in this way until such symptoms go away.4.8 Undesirable effects
A tabulated list of undesirable effects is outlined below:
The undesirable effects are listed according to organ systems and following frequencies:
Rare (≥1/10,000 to <1/1,000)
Not known (cannot be estimated from the available data)
| | | |
| --- | --- | --- |
| System organ class | Frequency | Adverse reaction |
| Infections and infestations | Not known | Superinfections by fungi or resistant organisms such as Pseudomonas. However, these are limited to the genitourinary tract |
| Blood and lymphatic system disorders | Rare Not known | Aplastic anaemia Agranulocytosis, leucopenia, granulocytopenia, haemolytic anaemia, thrombocytopenia,glucose¬6-phosphatedehydrogenase deficiency anaemia, megaloblasticanaemia and eosinophilia |
| Immune system disorders | Not known | Anaphylaxis, , angioneuroticoedema , cutaneous vasculitis and allergic skin reactions |
| Psychiatric disorders | Not known | psychotic reactions, depression, euphoria, confusion |
| Nervous system disorders | Not known | Benign intracranial hypertension, peripheral neuropathy including optic neuritis (sensory as well as motor involvement), nystagmus, vertigo, dizziness, headache and drowsiness. |
| Cardiac disorders | Rare | Collapse and cyanosis |
| Respiratory, thoracic and mediastinal disorders | Not known | Pulmonary fibrosis; possible association with lupus-erythematous-like syndrome. acute pulmonary reactions \\* subacute pulmonary reactions, \\* chronic pulmonary reactions, \\* cough, dyspnoea, |
| Gastrointestinal disorders | Not known | Sialaodenitis, pancreatitis, anorexia, emesis, abdominal pain, diarrhea and nausea |
| Hepatobiliary disorders | Not known | Chronic active hepatitis\\*\\*, hepatic necrosis, autoimmune hepatitis, cholestatic jaundice |
| Skin and subcutaneous tissue disorders | Not known | Lupus-like syndrome associated with pulmonary reaction. Drug Rash With Eosinophilia And Systemic Symptoms (DRESS syndrome), exfoliative dermatitis and erythema multiforme (including Stevens-Johnson Syndrome), maculopapular, erythematous or eczematous eruptions, urticaria, rash, and pruritis, Transient alopecia |
| Renal and urinary disorders | Not known | Interstitial nephritis, yellow or brown discolouration of urine, |
| General disorders and administration site conditions | Not known | Asthenia, fever, chills, drug fever and arthralgia |
| Investigations | Not known | False positive urinary glucose |
\\* Acute pulmonary reactions are commonly manifested by fever, chills, cough, chest pain, dyspnoea, pulmonary infiltration with consolidation or pleural effusion on chest x-ray, and eosinophilia. In subacute pulmonary reactions, fever and eosinophilia occur less often than in the acute form.
Chronic pulmonary reactions occur rarely in patients who have received continuous therapy for six months or longer and are more common in elderly patients. Changes in ECG have occurred, associated with pulmonary reactions
\\*\\*Can be fatal
\*\*Reporting of suspected side effects\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
\*\*Symptoms\*\*
Symptoms and signs of overdose include stomach irritation, nausea and vomiting.
\*\*Management\*\*
There is no specific antidote, however, nitrofurantoin can be haemodialysed if necessary. Standard treatment consists in the induction of emesis or gastric lavage in cases of recent ingestion (within one hour). Monitoring of full blood count, hepatic function and pulmonary function tests are recommended. A high fluid intake should be maintained to promote urinary excretion of nitrofurantoin.
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Antibacterials for systemic use, nitrofuran derivatives, ATC code: J01XE01
Nitrofurantoin is a broad spectrum antibacterial agent, active against the majority of urinary pathogens. It is bactericidal in renal tissue and throughout the urinary tract. The wide range of organisms sensitive to the bacterial activity include \*Escherichia coli, Enteroccus faecalis, Klebsiella species, Enterobacter species, Staphylococcus species: (eg S. aureus, S. saprophyticus, S. epidermidis)\*
Clinically, most common urinary pathogens are sensitive to nitrofurantoin. Some strains of \*Enterobacter and Klebsiella\* are resistant. Nitrofurantoin is not active against most strains of Proteus species or Serratia species. It has no activity against Pseudomonas species.5.2 Pharmacokinetic properties
\*\*Absorption\*\*
Each Nitrofurantoin CNX Therapeutics 100 mg Prolonged-Release Capsule contains two forms of nitrofurantoin. 25% of the dose is macrocrystalline nitrofurantoin which has slower dissolution and absorption than nitrofurantoin microcrystals. The remaining 75% of the dose is microcrystalline nitrofurantoin contained in a powdered blend which on exposure to gastric and intestinal fluids forms a gel matrix resulting in a modified release of active ingredient over time. Combined these systems provide a clinically effective bactericidal urine concentration at therapeutic doses.
\*\*Distribution\*\*
Plasma nitrofurantoin concentrations at therapeutic doses of the Nitrofurantoin 100mg Prolonged-Release Capsule are low, with peak levels usually less than 1 mcg/ml. Nitrofurantoin is highly soluble in urine to which it may impart a brown colour. Unlike many drugs the presence of food or agents delaying gastric emptying increases the bioavailability of the Nitrofurantoin 100mg Prolonged-Release Capsules.
\*\*Elimination\*\*
Approx. 20-25% of the total single dose of nitrofurantoin is recovered from the urine unchanged over 24 hours.5.3 Preclinical safety data
No data available.
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
\*\*Capsule content:\*\*
Talc
Maize starch
Carbomers
Povidone
Lactose monohydrate
Sucrose
Magnesium stearate
\*\*Capsule shell\*\*:
Iron oxide yellow
Iron oxide black
Titanium dioxide (E 171)
Gelatin
Indigo Carmine
\*\*Printing ink\*\*
Shellac
Propylene glycol (E 1520)
Strong ammonia solution
Water, purifed
Potassium hydroxide
Titanium dioxide (E 171)6.2 Incompatibilities
Not applicable.6.3 Shelf life
2 years6.4 Special precautions for storage
Do not store above 25° C.6.5 Nature and contents of container
Carton box containing standard PVC-PCTFE/Alu blisters with 2, 6, 7, 14 or 20 capsules each.
Pack sizes of 2 capsules (1 blister x 2 capsules), 6 capsules (3 blister x 2 capsules), 7 capsules (1 blister x 7 capsules), 14 capsules (2 blister x 7 capsules) or 20 capsules (2 blisters x 10 capsules).
Not all pack sizes may be marketed.6.6 Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
- Instruction Content
- ## Composition
Each prolonged-release hard capsule contains the equivalent of 100 mg nitrofurantoin in the form of nitrofurantoin macrocrystals and nitrofurantoin monohydrate.
\*\*Excipients with known effect:\*\*
Each capsule contains 74 mg lactose and 33 mg sucrose.
For the full list of excipients, see section 6.1.
## Pharmaceutical Form
Hard prolonged-release capsule
Each capsule is 19.4 mm long and 6.9 mm wide and has a blue opaque cap with “NTRF” debossed in white ink and a yellow opaque body.
## Clinical Particulars
4.1 Therapeutic indications
For the treatment of and prophylaxis against acute or recurrent, uncomplicated lower urinary tract infections or pyelitis either spontaneous or following surgical procedures. It is indicated in adults, children and infants over 12 years of age.
Nitrofurantoin is specifically indicated for the treatment of infections when due to susceptible strains of \*\*Escherichia coli\*\*, Enterococci, Staphylococci, \*\*Citrobacter\*\*, \*\*Klebsiella\*\* and \*\*Enterobacter\*\*.
Most strains of Proteus and \*\*Serratia\*\* are resistant. All \*\*Pseudomonas\*\* strains are resistant.
Nitrofurantoin is not indicated for the treatment of associated renal cortical or perinephric abscesses.4.2 Posology and method of administration
\*\*Posology\*\*
\*Adults and children over 12 years of age.\*
The dose should be taken with food or milk (e.g. at meal times).
Acute or recurrent uncomplicated UTI and pyelitis -100mg twice daily for seven days.
Surgical Prophylaxis - 100 mg twice daily on the day of the procedure and 3 days thereafter.
\*Elderly\*
Provided there is no significant renal impairment, in which nitrofurantoin is contraindicated, the dosage should be that for any normal adult.
See precaution and risks to elderly patients associated with long term therapy (see section 4.8).
\*Children under 12 years\*
Nitrofurantoin CNX Therapeutics 100mg Prolonged-Release Capsules is a fixed dosage and is therefore not suitable for children under 12 years.
\*Renal impairment\*
Nitrofurantoin is contraindicated in patients with renal dysfunction and in patients with an eGFR below of less than 45 ml/minute (see sections 4.3 & 4.4).
\*\*Method of administration\*\*
For oral use4.3 Contraindications
• Hypersensitivity to the active substance, other nitrofurans or to any of the excipients listed in section 6.1.
• Patients suffering from renal dysfunction with an eGFR below 45 ml/minute.
• G6PD deficiency (see also Section 4.6)
• Acute porphyria.
• In infants under three months of age as well as pregnant patients at term (during labour and delivery) because of the theoretical possibility of haemolytic anaemia in the foetus or in the newborn infant due to immature erythrocyte enzyme systems.4.4 Special warnings and precautions for use
Nitrofurantoin is not effective for the treatment of parenchymal infections of a unilaterally functioning kidney. A surgical cause for infection should be excluded in recurrent or severe cases.
Nitrofurantoin may be used with caution as short-course therapy only for the treatment of uncomplicated lower urinary tract infection in individual cases with an eGFR between 30-44 ml/min to treat resistant pathogens, when the benefits are expected to outweigh the risks.
Since pre-existing conditions may mask hepatic or pulmonary adverse reactions, nitrofurantoin should be used with caution in patients with pulmonary disease, hepatic dysfunction, neurological disorders and allergic diathesis.
Peripheral neuropathy and susceptibility to peripheral neuropathy, which may become severe or irreversible has occurred and may be life threatening. Therefore, treatment should be stopped at the first signs of neural involvement (paraesthesiae).
Nitrofurantoin should be used with caution in patients with anaemia, diabetes mellitus, electrolyte imbalance, debilitating conditions, and vitamin B (particularly folate) deficiency.
\*Pulmonary adverse reactions\*
Acute, subacute and chronic pulmonary reactions have been observed in patients treated with nitrofurantoin. If these reactions occur, nitrofurantoin should be discontinued immediately. Signs of pulmonary damage include difficulty and or pain when breathing, shortness of breath and coughing up blood or mucus.
\*Chronic pulmonary reactions\*
Chronic pulmonary reactions (including pulmonary fibrosis and diffuse interstitial pneumonitis) can develop insidiously and can often occur in elderly patients. Close monitoring of the lung diseaseof patients receiving long-term therapy is indicated (especially in the elderly).
\*Acute pulmonary reactions\*
Pulmonary reactions may be acute and usually occur within the first week of treatment. Increased vigilance for respiratory symptoms in patients who have just started therapy is warranted (especially in the elderly).
Urine may be coloured yellow or brown after taking Nitrofurantoin. Patients on Nitrofurantoin are susceptible to false positive urinary glucose (if tested for reducing substances).
Nitrofurantoin should be discontinued at any signs of haemolysis in those with suspected glucose-6-phosphate dehydrogenase deficiency.
Gastrointestinal reactions may be minimised by taking the drug with food or milk, or by adjustment of dosage.
\*Hepatotoxicity\*
Hepatic reactions, including hepatitis, autoimmune hepatitis, cholestatic jaundice, chronic active hepatitis, and hepatic necrosis, occur rarely. Fatalities have been reported. The onset of chronic active hepatitis may be insidious, and patients should be monitored periodically for changes in biochemical tests that would indicate liver injury. If hepatitis occurs, the drug should be withdrawn immediately and appropriate measures should be taken.
For long term treatment monitor the patient closely for appearance of hepatic or pulmonary symptoms and other evidence of toxicity.
Discontinue treatment with nitrofurantoin if otherwise unexplained pulmonary, hepatotoxic, haematological or neurological syndromes occur.
\*\*Excipients\*\*
Nitrofurantoin CNX Therapeutics 100 mg prolonged-release capsules contain lactose monohydrate and sucrose. Patients with rare hereditary problems of galactose intolerance, fructose intolerance, total lactase deficiency, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.4.5 Interaction with other medicinal products and other forms of interaction
1. Increased absorption with food or agents delaying gastric emptying.
2. Decreased absorption with magnesium trisilicate.
3. Decreased renal excretion of Nitrofurantoin by probenecid and sulfinpyrazone.
4. Decreased anti-bacterial activity by carbonic anhydrase inhibitors and urine alkalisation.
5. Anti-bacterial antagonism by quinolone anti-infectives.
6. Interference with some tests for glucose in urine.
7. As Nitrofurantoin belongs to the group of Antibacterials, it will have the following resulting interactions:
• Typhoid Vaccine (oral): Antibacterials inactivate oral typhoid vaccine.4.6 Fertility, pregnancy and breastfeeding
\*\*Pregnancy\*\*
Animal studies with nitrofurantoin have shown no teratogenic effects. Nitrofurantoin has been in extensive clinical use since 1952 and its suitability in human pregnancy has been well documented. However, as with all other drugs, the maternal side effects may adversely affect course of pregnancy. The drug should be used at the lowest dose as appropriate for a specific indication, only after careful assessment.
Nitrofurantoin is however contraindicated in infants under three months of age and in pregnant women during labour and delivery because of the possible risk of haemolysis of the infants immature red cells.
\*\*Breast-feeding\*\*
Breast feeding an infant known or suspected to have an erythrocyte enzyme deficiency (including G6PD deficiency), must be temporarily avoided, since Nitrofurantoin is detected in trace amounts in breast milk.
\*\*Fertility\*\*
No data available4.7 Effects on ability to drive and use machines
Nitrofurantoin CNX Therapeutics 100 mg Prolonged-Release Capsules may cause dizziness and drowsiness. Patients should be advised not to drive or operate machinery if affected in this way until such symptoms go away.4.8 Undesirable effects
A tabulated list of undesirable effects is outlined below:
The undesirable effects are listed according to organ systems and following frequencies:
Rare (≥1/10,000 to <1/1,000)
Not known (cannot be estimated from the available data)
| | | |
| --- | --- | --- |
| System organ class | Frequency | Adverse reaction |
| Infections and infestations | Not known | Superinfections by fungi or resistant organisms such as Pseudomonas. However, these are limited to the genitourinary tract |
| Blood and lymphatic system disorders | Rare Not known | Aplastic anaemia Agranulocytosis, leucopenia, granulocytopenia, haemolytic anaemia, thrombocytopenia,glucose¬6-phosphatedehydrogenase deficiency anaemia, megaloblasticanaemia and eosinophilia |
| Immune system disorders | Not known | Anaphylaxis, , angioneuroticoedema , cutaneous vasculitis and allergic skin reactions |
| Psychiatric disorders | Not known | psychotic reactions, depression, euphoria, confusion |
| Nervous system disorders | Not known | Benign intracranial hypertension, peripheral neuropathy including optic neuritis (sensory as well as motor involvement), nystagmus, vertigo, dizziness, headache and drowsiness. |
| Cardiac disorders | Rare | Collapse and cyanosis |
| Respiratory, thoracic and mediastinal disorders | Not known | Pulmonary fibrosis; possible association with lupus-erythematous-like syndrome. acute pulmonary reactions \\* subacute pulmonary reactions, \\* chronic pulmonary reactions, \\* cough, dyspnoea, |
| Gastrointestinal disorders | Not known | Sialaodenitis, pancreatitis, anorexia, emesis, abdominal pain, diarrhea and nausea |
| Hepatobiliary disorders | Not known | Chronic active hepatitis\\*\\*, hepatic necrosis, autoimmune hepatitis, cholestatic jaundice |
| Skin and subcutaneous tissue disorders | Not known | Lupus-like syndrome associated with pulmonary reaction. Drug Rash With Eosinophilia And Systemic Symptoms (DRESS syndrome), exfoliative dermatitis and erythema multiforme (including Stevens-Johnson Syndrome), maculopapular, erythematous or eczematous eruptions, urticaria, rash, and pruritis, Transient alopecia |
| Renal and urinary disorders | Not known | Interstitial nephritis, yellow or brown discolouration of urine, |
| General disorders and administration site conditions | Not known | Asthenia, fever, chills, drug fever and arthralgia |
| Investigations | Not known | False positive urinary glucose |
\\* Acute pulmonary reactions are commonly manifested by fever, chills, cough, chest pain, dyspnoea, pulmonary infiltration with consolidation or pleural effusion on chest x-ray, and eosinophilia. In subacute pulmonary reactions, fever and eosinophilia occur less often than in the acute form.
Chronic pulmonary reactions occur rarely in patients who have received continuous therapy for six months or longer and are more common in elderly patients. Changes in ECG have occurred, associated with pulmonary reactions
\\*\\*Can be fatal
\*\*Reporting of suspected side effects\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
\*\*Symptoms\*\*
Symptoms and signs of overdose include stomach irritation, nausea and vomiting.
\*\*Management\*\*
There is no specific antidote, however, nitrofurantoin can be haemodialysed if necessary. Standard treatment consists in the induction of emesis or gastric lavage in cases of recent ingestion (within one hour). Monitoring of full blood count, hepatic function and pulmonary function tests are recommended. A high fluid intake should be maintained to promote urinary excretion of nitrofurantoin.
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Antibacterials for systemic use, nitrofuran derivatives, ATC code: J01XE01
Nitrofurantoin is a broad spectrum antibacterial agent, active against the majority of urinary pathogens. It is bactericidal in renal tissue and throughout the urinary tract. The wide range of organisms sensitive to the bacterial activity include \*Escherichia coli, Enteroccus faecalis, Klebsiella species, Enterobacter species, Staphylococcus species: (eg S. aureus, S. saprophyticus, S. epidermidis)\*
Clinically, most common urinary pathogens are sensitive to nitrofurantoin. Some strains of \*Enterobacter and Klebsiella\* are resistant. Nitrofurantoin is not active against most strains of Proteus species or Serratia species. It has no activity against Pseudomonas species.5.2 Pharmacokinetic properties
\*\*Absorption\*\*
Each Nitrofurantoin CNX Therapeutics 100 mg Prolonged-Release Capsule contains two forms of nitrofurantoin. 25% of the dose is macrocrystalline nitrofurantoin which has slower dissolution and absorption than nitrofurantoin microcrystals. The remaining 75% of the dose is microcrystalline nitrofurantoin contained in a powdered blend which on exposure to gastric and intestinal fluids forms a gel matrix resulting in a modified release of active ingredient over time. Combined these systems provide a clinically effective bactericidal urine concentration at therapeutic doses.
\*\*Distribution\*\*
Plasma nitrofurantoin concentrations at therapeutic doses of the Nitrofurantoin 100mg Prolonged-Release Capsule are low, with peak levels usually less than 1 mcg/ml. Nitrofurantoin is highly soluble in urine to which it may impart a brown colour. Unlike many drugs the presence of food or agents delaying gastric emptying increases the bioavailability of the Nitrofurantoin 100mg Prolonged-Release Capsules.
\*\*Elimination\*\*
Approx. 20-25% of the total single dose of nitrofurantoin is recovered from the urine unchanged over 24 hours.5.3 Preclinical safety data
No data available.
## Pharmaceutical Particulars
6.1 List of excipients
\*\*Capsule content:\*\*
Talc
Maize starch
Carbomers
Povidone
Lactose monohydrate
Sucrose
Magnesium stearate
\*\*Capsule shell\*\*:
Iron oxide yellow
Iron oxide black
Titanium dioxide (E 171)
Gelatin
Indigo Carmine
\*\*Printing ink\*\*
Shellac
Propylene glycol (E 1520)
Strong ammonia solution
Water, purifed
Potassium hydroxide
Titanium dioxide (E 171)6.2 Incompatibilities
Not applicable.6.3 Shelf life
2 years6.4 Special precautions for storage
Do not store above 25° C.6.5 Nature and contents of container
Carton box containing standard PVC-PCTFE/Alu blisters with 2, 6, 7, 14 or 20 capsules each.
Pack sizes of 2 capsules (1 blister x 2 capsules), 6 capsules (3 blister x 2 capsules), 7 capsules (1 blister x 7 capsules), 14 capsules (2 blister x 7 capsules) or 20 capsules (2 blisters x 10 capsules).
Not all pack sizes may be marketed.6.6 Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
